Table 2:

Crude, adjusted and propensity-adjusted rate ratios for the risk of uveitis and scleritis among first-time users of oral bisphosphonate

Outcome	Crude RR	Adjusted* RR	Propensity-adjusted* RR
Uveitis	1.54 (1.33–1.78)	1.45 (1.25–1.68)	1.50 (1.29–1.73)
Scleritis	1.85 (1.68–2.05)	1.51 (1.34–1.68)	1.53 (1.39–1.70)

Note: RR = rate ratio.

^*Adjusted for age at index, sex, calendar time, use of sulfa-containing drugs, and comorbidities (ankylosing spondylitis, psoriasis, inflammatory bowel disease, rheumatoid arthritis, diabetes, systemic lupus erythematosus, sarcoidosis, multiple sclerosis).